Results 111 to 120 of about 1,204 (125)

Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases

Expert Review of Clinical Immunology
Yoshitaka Miyakawa, Kelly Gwathmey, Sophie Steeland   +2 more
exaly  

Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events

Muscle and Nerve
Madeline Singer, Colin Quinn, Chafic Karam   +2 more
exaly  

Case report: Rapid symptom relief in autoimmune encephalitis with efgartigimod: a three-patient case series

Frontiers in Immunology
Wenping Yang
exaly  

Case report: Rapid clinical improvement in acute exacerbation of MuSK-MG with efgartigimod

Frontiers in Immunology
Xiuming Guo
exaly  

Case report: Successful perioperative intervention with efgartigimod in a patient in myasthenic crisis

Frontiers in Immunology
Shahar Shelly
exaly  

Efficacy and safety of efgartigimod in patients with neurological autoimmune diseases

Immunology Letters
Huiqin Liu
exaly  

Case report: Recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod

Frontiers in Neurology
Ryuta Kinno, Shinichi Ohashi
exaly  

Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod

Frontiers in Immunology
Hongjun Hao, Zhaoxia Wang, Yikang Wang   +2 more
exaly  

Perioperative Safety and Efficacy of Efgartigimod for Thymoma-Associated Myasthenia Gravis: A Prospective, Multicenter, Phase II Clinical Trial

Journal of Thoracic Oncology
Dong Jihong, Jian-Yong Ding, Xiangnan Xu   +2 more
exaly  

Efgartigimod in the treatment of Guillain–Barré syndrome

Journal of Neurology
Wei Zhang
exaly